Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin DR for Active Moderate Crohn's Disease
NCT02240121Phase 3Terminated
- Sponsor
- Valeant Pharmaceuticals
- Start
- Aug 2014
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Rifaximin EIR 800 mg with Placebo (2 arms). Primary endpoints: Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 1) at 16 weeks, Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 2) at 16 weeks and 2 more. Started Aug 2014; status: terminated.
02
Drugs
rifaximin
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02240121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02240121.